Drug intelligence / Profile preview

Neo-T

Development stage: Phase 1
Lead developer: BGI
Modality: Cell Therapies
Administration: Intravenous

Overview

Neo-T is an investigational cell therapy being studied for the treatment of advanced solid tumors, including melanoma and certain types of lung cancer. In a clinical trial, Neo-T is administered in combination with an anti-PD1 medication to evaluate its safety and preliminary efficacy in patients whose cancers have not responded to standard treatments. The precise mechanism of action for Neo-T has not been disclosed in public sources as of April 2025, but it is under evaluation as a novel approach for immunotherapy in oncology.

Other names: Neoantigen-reactive T cellsNeoantigen-specific T cell therapy

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on Neo-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neo-T.

Explore the full profile